Heil Emily L, Townsend Mary L, Shipp Kenneth, Clarke Amy, Johnson Melissa D
Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
AIDS Res Treat. 2010;2010:856542. doi: 10.1155/2010/856542. Epub 2010 Sep 26.
Introduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to their underlying liver disease. This study assessed the incidence of hepatotoxicity in HIV/HCV co-infected patients in two outpatient infectious diseases clinics. Methods. HIV/HCV co-infected adults were included in this retrospective study if they were PI or NNRTI naïve at their first clinic visit and were initiated on an NNRTI- and/or PI-based antiretroviral regimen. Patients were excluded if they had active or chronic hepatitis B virus (HBV). The primary objective was to determine the overall incidence of severe hepatotoxicity. Results. Fifty-six of the 544 patients identified met inclusion criteria. The incidence of severe hepatotoxicity was 10.7% (6/56 patients). Severe hepatotoxicity occurred with efavirenz (N = 2), nevirapine (N = 1), indinavir (N = 1), nelfinavir (N = 1), and saquinavir/ritonavir (N = 1). Conclusion. The incidence of severe hepatotoxicity appears to be low in this retrospective analysis of HIV/HCV co-infected patients receiving a PI-and/or NNRTI-based regimen.
引言。由于合并潜在的肝脏疾病，肝毒性是艾滋病毒/丙型肝炎病毒（HCV）合并感染患者所关注的问题。本研究评估了两家门诊传染病诊所中艾滋病毒/HCV合并感染患者的肝毒性发生率。方法。如果艾滋病毒/HCV合并感染的成年人在首次就诊时未接受蛋白酶抑制剂（PI）或非核苷类逆转录酶抑制剂（NNRTI）治疗，并开始接受基于NNRTI和/或PI的抗逆转录病毒治疗方案，则纳入本回顾性研究。如果患者患有活动性或慢性乙型肝炎病毒（HBV）感染，则将其排除。主要目的是确定严重肝毒性的总体发生率。结果。在确定的544例患者中，有56例符合纳入标准。严重肝毒性的发生率为10.7%（56例患者中有6例）。使用依非韦伦（N = 2）、奈韦拉平（N = 1）、茚地那韦（N = 1）、奈非那韦（N = 1）和沙奎那韦/利托那韦（N = 1）时出现了严重肝毒性。结论。在这项对接受基于PI和/或NNRTI方案治疗的艾滋病毒/HCV合并感染患者的回顾性分析中，严重肝毒性的发生率似乎较低。
